Literature DB >> 3780127

Ritodrine pharmacokinetics.

B R Kuhnert, T L Gross, P M Kuhnert, P Erhard, W T Brashar.   

Abstract

The purpose of this study was to add to the limited information available regarding the pharmacology of ritodrine in the peripartum period when treatment fails and labor is not inhibited. Plasma or urine samples from eight parturients and 13 infants were studied; in addition plasma samples at delivery were obtained from a total of 26 mothers and infants. All the mothers received ritodrine in the 24 hours before delivery. Plasma and urine ritodrine (free and conjugated) were determined with HPLC by electrochemical detection. In maternal plasma, an apparent rapid distribution phase with a t1/2 of 32 +/- 21 minutes was followed by a prolonged equilibrium phase with a t1/2 of 17 +/- 10 hours. Seventy-six percent of the ritodrine excreted by the mother was in the form of a conjugate. Ninety percent of the ritodrine excreted by the neonate was also excreted in the form of a conjugate.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3780127     DOI: 10.1038/clpt.1986.241

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  Ritodrine sulphation in the human liver and duodenal mucosa: interindividual variability.

Authors:  G M Pacifici; M C Quilici; B Giulianetti; R Spisni; M Nervi; L Giuliani; R Gomeni
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jan-Mar       Impact factor: 2.441

2.  Pharmacokinetics of ritodrine diastereomers in patients pregnant with singletons and twins.

Authors:  A Konda; T Ito; H Yoshida; T Toda; T Hayakawa; N Inotsume
Journal:  Eur J Clin Pharmacol       Date:  2009-05-27       Impact factor: 2.953

3.  Ritodrine pharmacokinetics in twin pregnancy patients.

Authors:  A Konda; A Nodai; M Soma; Y Koga; H Yoshida; T Toda; T Hayakawa; N Inotsume
Journal:  Eur J Clin Pharmacol       Date:  2007-12-18       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of beta-agonists.

Authors:  D J Morgan
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.